8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
May 13, 2026·SEC
Material company update
Mar 9, 2026·SEC
ARS Pharmaceuticals, Inc.(SPRY)Earnings, Financials & Key Ratios
SPRY•NASDAQ
Price updated Jun 19, 2026
AboutARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.Show more
- Revenue$84M-5.5%
- EBITDA-$178M-5828.1%
- Net Income-$171M-2241.8%
- EPS (Diluted)-1.74-2327.9%
- Gross Margin75.77%-1.5%
- EBITDA Margin-211.3%-6170.8%
- Operating Margin-212.92%-6056.9%
- Net Margin-203.25%-2365.5%
- ROE-92.33%-2914.3%
SPRY Key Insights
ARS Pharmaceuticals, Inc. (SPRY) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 36.4%
- ✓Share count reduced 3.7% through buybacks
✗Weaknesses
- ✗Profits declining 176.2% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when SPRY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SPRY Price & Volume
ARS Pharmaceuticals, Inc. (SPRY) stock price & volume — 10-year historical chart
Loading chart...
SPRY Growth Metrics
ARS Pharmaceuticals, Inc. (SPRY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years36.42%
3 Years300.09%
TTM1.92%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-1165.02%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1082.35%
Return on Capital
10 Years-61.11%
5 Years-32.4%
3 Years-28.66%
Last Year-58.24%
SPRY Recent Earnings
ARS Pharmaceuticals, Inc. (SPRY) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 4/12 qtrs (50%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.61-15.1%
$0.53
Rev
$23M+2.2%
$22M
Q2 2026
Mar 9, 2026Metric
Actual
Est
EPS
$0.42+0.0%
$0.42
Rev
$28M+9.7%
$26M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.52-15.6%
$0.45
Rev
$33M+27.0%
$26M
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.46-12.2%
$0.41
Rev
$16M-43.2%
$28M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.61vs $0.53-15.1% | $23Mvs $22M+2.2% |
| Q2 2026 | Mar 9, 2026 | $0.42vs $0.42+0.0% | $28Mvs $26M+9.7% |
| Q4 2025 | Nov 10, 2025 | $0.52vs $0.45-15.6% | $33Mvs $26M+27.0% |
| Q3 2025 | Aug 13, 2025 | $0.46vs $0.41-12.2% | $16Mvs $28M-43.2% |
Based on last 12 quarters of dataView full earnings history →
SPRY Peer Comparison
ARS Pharmaceuticals, Inc. (SPRY) competitors in Drug Delivery Technology Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ADMA | 1.93B | 8.31 | 13.85 | 19.63% | 32.43% | 38.97% | 0.17 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 NTRA | 33.14B | 231.41 | -152.24 | 35.9% | -9.05% | -15.13% | 0.13 | |
 TLRY | 551.15M | 4.73 | -0.14 | 4.84% | -252.55% | -136.55% | 0.22 | |
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 AVDL | 2.1B | 21.64 | -42.43 | 5.05% | -0.11% | -0.33% | 0.02 | |
 ABBV | 383.17B | 216.63 | 91.41 | 8.57% | 6.91% | 62.15% | ||
 ALK | 5.65B | 49.26 | 56.62 | 21.34% | 0.7% | 2.43% | 1.67 |
Compare SPRY vs Peers
ARS Pharmaceuticals, Inc. (SPRY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SPRY Income Statement
ARS Pharmaceuticals, Inc. (SPRY) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 17.84M | 5.51M | 1.32M | 30K | 89.15M | 84.28M | 98.99M |
Revenue Growth % | - | - | - | -69.13% | -76.1% | -97.72% | 297063.33% | -5.46% | 1.92% |
Cost of Goods Sold | 1.42M | 1.55M | 14.07M | 213K | 17.12M | 0 | 20.56M | 20.42M | 22.66M |
COGS % of Revenue | - | - | 78.89% | 3.87% | 1300.91% | - | 23.06% | 24.23% | - |
Gross Profit | -1.42M▲ 0% | -1.55M▼ 8.9% | 3.77M▲ 343.5% | 5.29M▲ 40.6% | -15.8M▼ 398.6% | 30K▲ 100.2% | 68.59M▲ 228540.0% | 63.85M▼ 6.9% | 76.32M▲ 0% |
Gross Margin % | - | - | 21.11% | 96.13% | -1200.91% | 100% | 76.94% | 75.77% | 77.1% |
Gross Profit Growth % | - | -8.87% | 343.53% | 40.58% | -398.58% | 100.19% | 228540% | -6.91% | - |
Operating Expenses | 16.9M | 22.52M | 4.23M | 24.75M | 19.71M | 67.55M | 71.67M | 243.3M | 278.74M |
OpEx % of Revenue | - | - | 23.74% | 449.46% | 1497.87% | 225166.67% | 80.4% | 288.69% | - |
Selling, General & Admin | 2.1M | 1.02M | 4.23M | 4.69M | 18.66M | 47.28M | 0 | 230.12M | 261.22M |
SG&A % of Revenue | - | - | 23.74% | 85.13% | 1417.63% | 157613.33% | - | 273.05% | - |
Research & Development | 14.8M | 21.5M | 14.07M | 20.27M | 18.38M | 20.27M | 19.58M | 13.18M | 14.56M |
R&D % of Revenue | - | - | 78.89% | 368.2% | 1396.35% | 67553.33% | 21.96% | 15.64% | - |
Other Operating Expenses | 0 | 0 | -14.07M | -213K | -17.32M | 0 | 52.09M | 0 | 1000K |
Operating Income | -18.32M▲ 0% | -24.07M▼ 31.4% | -469K▲ 98.1% | -19.45M▼ 4048.0% | -35.52M▼ 82.6% | -67.52M▼ 90.1% | -3.08M▲ 95.4% | -179.45M▼ 5720.6% | -202.42M▲ 0% |
Operating Margin % | - | - | -2.63% | -353.32% | -2698.78% | -225066.67% | -3.46% | -212.92% | -204.49% |
Operating Income Growth % | - | -31.37% | 98.05% | -4047.97% | -82.56% | -90.11% | 95.43% | -5720.56% | - |
EBITDA | -16.9M | -22.52M | -463K | -19.24M | -35.2M | -67.45M | -3M | -178.08M | -198.97M |
EBITDA Margin % | - | - | -2.6% | -349.46% | -2674.54% | -224823.33% | -3.37% | -211.3% | -201.01% |
EBITDA Growth % | - | -33.26% | 97.94% | -4055.72% | -82.93% | -91.63% | 95.55% | -5828.13% | -644.65% |
D&A (Non-Cash Add-back) | 1.42M | 1.55M | 6K | 213K | 319K | 73K | 79K | 1.37M | 3.44M |
EBIT | -17.58M | -23.97M | -469K | -19.45M | -35.52M | -67.52M | -3.08M | -179.45M | -197.64M |
Net Interest Income | 0 | 100K | 371K | 694K | 0 | 0 | 0 | 8.07M | -473K |
Interest Income | 43K | 100K | 400K | 800K | 0 | 0 | 0 | 10.67M | 1.97M |
Interest Expense | 0 | - | 29K | 106K | 0 | 0 | 0 | 2.6M | 2.44M |
Other Income/Expense | 741K | 100K | -596K | -789K | 834K | 13.15M | 11.37M | 8.07M | 4.36M |
Pretax Income | -17.58M▲ 0% | -23.97M▼ 36.3% | -1.06M▲ 95.6% | -20.24M▼ 1800.8% | -34.68M▼ 71.3% | -54.37M▼ 56.8% | 8.29M▲ 115.2% | -171.38M▼ 2168.3% | -198.06M▲ 0% |
Pretax Margin % | - | - | -5.97% | -367.65% | -2635.41% | -181216.67% | 9.29% | -203.35% | -200.08% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 288K | -80K | -80K |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 3.48% | 0.05% | 0.04% |
Net Income | -17.58M▲ 0% | -23.97M▼ 36.3% | -1.06M▲ 95.6% | -20.24M▼ 1800.8% | -34.68M▼ 71.3% | -54.37M▼ 56.8% | 8M▲ 114.7% | -171.3M▼ 2241.8% | -197.98M▲ 0% |
Net Margin % | - | - | -5.97% | -367.65% | -2635.41% | -181216.67% | 8.97% | -203.25% | -200% |
Net Income Growth % | - | -36.34% | 95.56% | -1800.75% | -71.33% | -56.75% | 114.71% | -2241.76% | -1165.02% |
Net Income (Continuing) | -17.58M | -23.97M | -1.06M | -20.24M | -34.68M | -54.37M | 8M | -171.3M | -197.98M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.53▲ 0% | -0.72▼ 35.8% | -0.03▲ 95.7% | -0.70▼ 2180.1% | -0.87▼ 24.3% | -0.57▲ 34.5% | 0.08▲ 113.7% | -1.74▼ 2327.9% | -1.99▲ 0% |
EPS Growth % | - | -35.85% | 95.74% | -2180.13% | -24.29% | 34.48% | 113.7% | -2327.91% | -1082.35% |
EPS (Basic) | -0.53 | -0.72 | -0.03 | -0.70 | -0.87 | -0.57 | 0.08 | -1.74 | - |
Diluted Shares Outstanding | 33.07M | 33.07M | 34.7M | 28.87M | 39.96M | 95.22M | 102.39M | 98.57M | 99.3M |
Basic Shares Outstanding | 33.07M | 33.07M | 34.7M | 28.87M | 39.96M | 95.22M | 96.94M | 98.57M | 99.3M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
SPRY Balance Sheet
ARS Pharmaceuticals, Inc. (SPRY) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 20.78M | 10.53M | 26.38M | 60.73M | 277.7M | 231.56M | 334.3M | 284.9M | 245.24M |
Cash & Short-Term Investments | 20.16M | 9.98M | 24.52M | 60.06M | 274.38M | 228.36M | 314.02M | 244.99M | 200.97M |
Cash Only | 20.16M | 9.98M | 24.52M | 60.06M | 210.52M | 70.97M | 50.82M | 41.32M | 24.32M |
Short-Term Investments | 0 | 0 | 0 | 0 | 63.86M | 157.39M | 263.2M | 203.67M | 176.65M |
Accounts Receivable | 0 | 0 | 384K | 1K | 0 | 795K | 9.16M | 25.35M | 28.66M |
Days Sales Outstanding | - | - | 7.86 | 0.07 | - | 9.67K | 37.51 | 109.78 | 107.43 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 5.21M | 8.37M | 8.82M |
Days Inventory Outstanding | - | - | - | - | - | - | 92.54 | 149.57 | 135.71 |
Other Current Assets | 618K | 552K | 0 | 0 | 1.01M | 0 | 1.23M | 6.19M | 6.79M |
Total Non-Current Assets | 6.77M | 5.12M | 25K | 716K | 3.73M | 1.63M | 16.86M | 42.76M | 42.34M |
Property, Plant & Equipment | 6.02M | 4.57M | 23K | 693K | 774K | 824K | 1.07M | 2.46M | 2.29M |
Fixed Asset Turnover | - | - | 775.43x | 7.95x | 1.70x | 0.04x | 83.63x | 34.19x | 39.45x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 7.68M | 14.45M | 14.18M |
Long-Term Investments | 750K | 550K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 2K | 23K | 2.96M | 801K | 8.11M | 25.84M | 25.87M |
Total Assets | 27.55M▲ 0% | 15.65M▼ 43.2% | 26.41M▲ 68.8% | 61.45M▲ 132.7% | 281.44M▲ 358.0% | 233.19M▼ 17.1% | 351.15M▲ 50.6% | 327.65M▼ 6.7% | 287.57M▲ 0% |
Asset Turnover | - | - | 0.68x | 0.09x | 0.00x | 0.00x | 0.25x | 0.26x | 0.30x |
Asset Growth % | - | -43.2% | 68.77% | 132.69% | 358.02% | -17.14% | 50.59% | -6.69% | 93.71% |
Total Current Liabilities | 5.14M | 17.93M | 8.21M | 8.19M | 5.44M | 2.39M | 23.44M | 39.15M | 49.61M |
Accounts Payable | 775K | 3.52M | 1.22M | 1.79M | 1.66M | 759K | 9.87M | 5.72M | 4.71M |
Days Payables Outstanding | 199.21 | 830.58 | 31.62 | 3.06K | 35.37 | - | 175.25 | 102.32 | 138.39 |
Short-Term Debt | 3.53M | 12.3M | 2.56M | 3.48M | 0 | 237K | 0 | 588K | 592K |
Deferred Revenue (Current) | 0 | 0 | 3.52M | 1.46M | 0 | 0 | 557K | 0 | 746K |
Other Current Liabilities | 841K | 2.11M | 0 | 660K | 1.46M | 1.08M | 2.29M | 32.83M | 44.31M |
Current Ratio | 4.04x | 0.59x | 3.21x | 7.42x | 51.01x | 96.85x | 14.26x | 7.28x | 4.94x |
Quick Ratio | 4.04x | 0.59x | 3.21x | 7.42x | 51.01x | 96.85x | 14.04x | 7.06x | 4.77x |
Cash Conversion Cycle | - | - | - | - | - | - | -45.19 | 157.03 | 104.76 |
Total Non-Current Liabilities | 4.21M | 3.32M | 32.25M | 84.53M | 3.1M | 37K | 70.92M | 174.25M | 176.65M |
Long-Term Debt | 0 | 0 | 7.46M | 4.93M | 0 | 0 | 0 | 96.37M | 96.52M |
Capital Lease Obligations | 4.21M | 3.32M | 0 | 480K | 251K | 37K | 0 | 0 | 1.07M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 21.35M | 76.12M | 2.85M | 0 | 69.38M | 76.75M | 79.15M |
Total Liabilities | 9.35M | 21.25M | 40.46M | 92.72M | 8.55M | 2.43M | 94.36M | 213.39M | 226.26M |
Total Debt | 7.73M | 15.62M | 10.02M | 9.03M | 481K | 274K | 42K | 96.96M | 97.11M |
Net Debt | -12.43M | 5.64M | -14.5M | -51.03M | -210.04M | -70.7M | -50.77M | 55.65M | 72.79M |
Debt / Equity | 0.43x | - | - | - | 0.00x | 0.00x | 0.00x | 0.85x | 1.58x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -0.49x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | -0.37x |
Interest Coverage | - | - | -16.17x | -183.53x | - | - | - | -69.05x | -80.97x |
Total Equity | 18.2M▲ 0% | -5.6M▼ 130.8% | -14.05M▼ 150.8% | -31.27M▼ 122.5% | 272.89M▲ 972.7% | 230.76M▼ 15.4% | 256.8M▲ 11.3% | 114.26M▼ 55.5% | 61.31M▲ 0% |
Equity Growth % | - | -130.79% | -150.79% | -122.52% | 972.7% | -15.44% | 11.28% | -55.51% | -165.91% |
Book Value per Share | 0.55 | -0.17 | -0.40 | -1.08 | 6.83 | 2.42 | 2.51 | 1.16 | 0.62 |
Total Shareholders' Equity | 18.2M | -5.6M | -14.05M | -31.27M | 272.89M | 230.76M | 256.8M | 114.26M | 61.31M |
Common Stock | 0 | 0 | 223K | 3K | 9K | 10K | 10K | 10K | 10K |
Retained Earnings | -39.82M | -63.79M | -22.01M | -42.26M | -76.94M | -131.3M | -123.31M | -294.6M | -355.22M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 407K | 49K | 220K | 125K | -96K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SPRY Cash Flow Statement
ARS Pharmaceuticals, Inc. (SPRY) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -16.88M | -18.9M | 9.07M | -17.56M | -40.08M | -59.27M | 13.55M | -170.87M | -175.07M |
Operating CF Margin % | - | - | 50.86% | -318.94% | -3045.44% | -197553.33% | 15.2% | -202.74% | - |
Operating CF Growth % | - | -11.99% | 148% | -293.6% | -128.22% | -47.88% | 122.86% | -1361.19% | -882.97% |
Net Income | -17.58M | -23.97M | -1.06M | -20.24M | -34.68M | -54.37M | 8M | -171.3M | -197.98M |
Depreciation & Amortization | 1.42M | 1.55M | 6K | 213K | 319K | 73K | -7.17M | 1.37M | 1.48M |
Stock-Based Compensation | 0 | 0 | 3.54M | 2.83M | 5.84M | 9.23M | 14.53M | 22.09M | 24.22M |
Deferred Taxes | 0 | 0 | 1K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 2.04M | 223K | 121K | -4K | 1.2M | -6.88M | 0 | -3.03M | -1.81M |
Working Capital Changes | -433K | 3.3M | 6.46M | -356K | -12.75M | -7.33M | -1.81M | -20M | -988K |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | -8.18M | -17.2M | -16.92M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | -5.95M | -21.99M | -13.83M |
Change in Payables | 513K | 4.01M | 1.79M | 0 | -10.29M | -2.78M | 16.43M | 18.88M | 25.03M |
Cash from Investing | -449K | -96K | -917K | -55K | -199K | -87.18M | -106.1M | 56.77M | 55.49M |
Capital Expenditures | -449K | -96K | -917K | -55K | -199K | -175K | -563K | -339K | -248K |
CapEx % of Revenue | - | - | 5.14% | 1% | 15.12% | 583.33% | 0.63% | 0.4% | 0.25% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | -7.5M | -7.86M | -7.86M |
Cash from Financing | 19.4M | 8.61M | 5.1M | 53.16M | 190.73M | 6.9M | 72.4M | 104.6M | 104.03M |
Debt Issued (Net) | -852K | 8.59M | 5M | -1.82M | -8.68M | 0 | 69.38M | 96.26M | 96.26M |
Equity Issued (Net) | 20.25M | 19K | 409.21M | 54.81M | 570K | 6.9M | 3.02M | 5.68M | 5.02M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | -409.11M | 169K | 198.84M | 0 | 0 | 2.66M | 2.76M |
Net Change in Cash | 2.08M▲ 0% | -10.18M▼ 590.8% | 14.17M▲ 239.1% | 35.54M▲ 150.8% | 150.46M▲ 323.3% | -139.55M▼ 192.7% | -20.15M▲ 85.6% | -9.5M▲ 52.9% | -15.54M▲ 0% |
Free Cash Flow | -17.32M▲ 0% | -18.99M▼ 9.6% | 8.15M▲ 142.9% | -17.62M▼ 316.0% | -40.28M▼ 128.6% | -59.44M▼ 47.6% | 12.98M▲ 121.8% | -171.21M▼ 1418.5% | -175.32M▲ 0% |
FCF Margin % | - | - | 45.72% | -319.94% | -3060.56% | -198136.67% | 14.57% | -203.14% | -177.11% |
FCF Growth % | - | -9.64% | 142.93% | -316.04% | -128.64% | -47.58% | 121.85% | -1418.48% | -732.67% |
FCF per Share | -0.52 | -0.57 | 0.23 | -0.61 | -1.01 | -0.62 | 0.13 | -1.74 | -1.77 |
FCF Conversion (FCF/Net Income) | 0.96x | 0.79x | -8.52x | 0.87x | 1.16x | 1.09x | 1.69x | 1.00x | 0.89x |
Interest Paid | 0 | 0 | 325K | 576K | 366K | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SPRY Key Ratios
ARS Pharmaceuticals, Inc. (SPRY) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -380.61% | - | - | -28.71% | -21.59% | 3.28% | -92.33% | -153.61% |
Return on Invested Capital (ROIC) | -621.14% | - | - | - | -45.43% | -1.26% | -71.6% | -113.28% |
Gross Margin | - | 21.11% | 96.13% | -1200.91% | 100% | 76.94% | 75.77% | 77.1% |
Net Margin | - | -5.97% | -367.65% | -2635.41% | -181216.67% | 8.97% | -203.25% | -200% |
Debt / Equity | - | - | - | 0.00x | 0.00x | 0.00x | 0.85x | 1.58x |
Interest Coverage | - | -16.17x | -183.53x | - | - | - | -69.05x | -80.97x |
FCF Conversion | 0.79x | -8.52x | 0.87x | 1.16x | 1.09x | 1.69x | 1.00x | 0.89x |
Revenue Growth | - | - | -69.13% | -76.1% | -97.72% | 297063.33% | -5.46% | 1.92% |
Related:SPRY Dividend History·SPRY Revenue History·SPRY Price History·SPRY P/E History·SPRY Financial Ratios·SPRY Institutional Holders
SPRY SEC Filings & Documents
ARS Pharmaceuticals, Inc. (SPRY) SEC filings — annual & quarterly reports (10-K, 10-Q)
SPRY Frequently Asked Questions
ARS Pharmaceuticals, Inc. (SPRY) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
ARS Pharmaceuticals, Inc. (SPRY) reported $99.0M in revenue for fiscal year 2025.
ARS Pharmaceuticals, Inc. (SPRY) saw revenue decline by 5.5% over the past year.
ARS Pharmaceuticals, Inc. (SPRY) reported a net loss of $198.0M for fiscal year 2025.
Dividend & Returns
ARS Pharmaceuticals, Inc. (SPRY) has a return on equity (ROE) of -92.3%. Negative ROE indicates the company is unprofitable.
ARS Pharmaceuticals, Inc. (SPRY) had negative free cash flow of $175.3M in fiscal year 2025, likely due to heavy capital investments.